Shane Knowles

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

Nahum Sonenberg, H. Atkins, N. Sonenberg, 2000, Nature Medicine.

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

H. Atkins, J. Hiscott, J. Bell, 2003, Cancer cell.

The Murine Double-Stranded RNA-Dependent Protein Kinase PKR Is Required for Resistance to Vesicular Stomatitis Virus

N. Sonenberg, J. Bell, E. Brown, 2000, Journal of Virology.

Efficacy of Systemically Administered Mutant Vesicular Stomatitis Virus (VSVΔ51) Combined with Radiation for Nasopharyngeal Carcinoma

A. Hui, B. O'Sullivan, P. Gullane, 2008, Clinical Cancer Research.

The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers

J. Diallo, B. Vanderhyden, D. Kirn, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Viral vector production in the integrity® iCELLis® single-use fixed-bed bioreactor, from bench-scale to industrial scale

Jean-Christophe Drugmand, Shane Knowles, J. Castillo, 2013, BMC Proceedings.